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We report 2 patients with invasive aspergillosis after 
infection with pandemic (H1N1) 2009. Inﬂ  uenza  viruses 
are known to cause immunologic defects and impair ciliary 
clearance. These defects, combined with high-dose corti-
costeroids prescribed during inﬂ  uenza-associated adult re-
spiratory distress syndrome, may be novel risk factors pre-
disposing otherwise immunocompetent patients to invasive 
aspergillosis.
I
nvasive aspergillosis has emerged as a major cause of 
life-threatening infections in immunocompromised pa-
tients. Patients with prolonged neutropenia, inherited im-
munodeﬁ   ciency, or those receiving immunosuppressive 
agents are at risk for infection (1). Recent evidence has 
identiﬁ  ed other populations at risk for invasive aspergil-
losis, including those with chronic obstructive pulmonary 
disease (COPD) and nontransplant patients in intensive 
care units (ICUs) (2,3). We recently treated 2 immunocom-
petent patients who had invasive aspergillosis after infec-
tion with pandemic (H1N1) 2009 and are aware of similar 
cases at other centers (4).
Inﬂ  uenza strains have been reported to cause cell-me-
diated defects, disruption of normal ciliary clearance (5), 
and leukopenia (6). These abnormalities and use of high-
dose corticosteroids during treatment for inﬂ  uenza-associ-
ated acute respiratory distress syndrome (ARDS) may form 
a unique group of risk factors for invasive aspergillosis.
The Patients
Patient 1 was a 28-year-old man (college student) with 
no unusual medical history (body mass index 18 kg/m2) 
who was hospitalized after having shortness of breath for 
1–1.5 weeks. Upon admission, he required intubation for 
respiratory failure. A chest radiograph showed multilobar 
pneumonia. His condition was complicated by pneumotho-
races and bronchopleural ﬁ  stula formation secondary to 
barotrauma during mechanical ventilation. A nasopharyn-
geal inﬂ  uenza swab specimen obtained at admission was 
positive for inﬂ  uenza A by PCR and was conﬁ  rmed as pan-
demic (H1N1) 2009 by the New York State Health Depart-
ment. Results of bronchoscopic evaluation for copathogens 
were negative. The patient was not treated with antivirus 
medication during his hospitalization because the diagnosis 
was made outside the optimal treatment time frame.
He received high-dose methylprednisolone (1 mg/kg/
day) for ARDS for 28 days and later underwent bronchos-
copy because of poor clinical improvement. Necrosis of 
the airway wall and cartilage, with extensive hyphae, was 
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DOI: 10.3201/eid1606.100165found and tissue cultures showed Aspergillus fumigatus. 
Intravenous voriconazole was initiated (6 mg/kg every 12 
h [2 doses], then 4 mg/kg every 12 h for 24 days), but his 
clinical condition deteriorated; micafungin (100 mg/d) was 
added and continued for 14 days until he was transferred to 
another hospital on day 52.
On admission, tests showed lymphopenia (700 cells/
mm3) and renal and respiratory failure. A. fumigatus was 
isolated from sputum, bronchoscopy, and pleural ﬂ  uid cul-
tures. A computed tomographic scan of the chest showed 
multifocal pneumonia. He was initially treated with am-
photericin B lipid complex, cefepime, metronidazole, 
tobramycin, and vancomycin. The patient became hemo-
dynamically unstable and required multiple vasopressors. 
On day 70, he had cardiopulmonary arrest and died. An 
autopsy was not performed.
Patient 2 was a 51-year-old man (ofﬁ  ce worker) with 
no unusual medical history (body mass index 24.5 kg/m2) 
who was hospitalized for fatigue and fever (<104°F). A 
chest radiograph showed bilateral inﬁ  ltrates. Laboratory 
tests showed a leukocyte count of 1,500 cells/mm3 and a 
thrombocyte count of 65,000 cells/mm3. A bone marrow 
biopsy specimen was negative for malignancy. A computed 
tomographic scan of the chest showed diffuse alveolar con-
solidation. Broad-spectrum antimicrobial drugs (vancomy-
cin, aztreonam, azithromycin, and ﬂ  uconazole) were given 
but the patient’s respiratory status rapidly deteriorated and 
he was intubated on hospital day 2. Bronchoscopy showed 
alveolar hemorrhage, and he underwent video-assisted tho-
racoscopy and right lung wedge resection. 
Virus cultures were positive for inﬂ  uenza A and veri-
ﬁ  ed as pandemic (H1N1) 2009 by the New York State 
Health Department. Antiviral treatment was not started 
because the diagnosis was made >48 hours after the onset 
of symptoms. A lung biopsy specimen showed widespread 
alveolar hemorrhage without fungal elements. Develop-
ment of ARDS prompted administration of methylpred-
nisolone (1 mg/kg/day for 3 days); his fever was quickly 
reduced. Once the methylprednisolone dose was tapered, 
fever recurred. Bronchoscopy on day 12 showed spontane-
ous bleeding from the right middle lobe and multiple blood 
clots. Pathologic examination identiﬁ  ed fungal hyphae and 
A. fumigatus grew in culture. Treatment with intravenous 
voriconazole (6 mg/kg every 12 h [2 doses], followed by 4 
mg/kg every 12 h) was initiated and continued for 3 days 
until he was transferred to another hospital on day 16.
At the new hospital, broad-spectrum antimicrobial 
therapy (linezolid, cefepime, tobramycin, oseltamivir, and 
voriconazole) was initiated. The patient showed decompen-
sation over the next 72 h; his family withdrew care on day 
21, and the patient died later that day. An autopsy showed 
severe pulmonary congestion, hemorrhage, and acute ne-
crotizing bronchopneumonia. Several fungal abscesses 
consistent with Aspergillus spp. were identiﬁ  ed in the lung, 
thyroid gland, and liver.
Conclusions
The number of patients at risk for invasive aspergillosis 
continues to increase. Recently, patients with COPD who 
are receiving long-term corticosteroids and immunocom-
petent ICU patients have been identiﬁ  ed as nontraditional 
hosts at risk for invasive aspergillosis. Mortality rates in 
these groups are high, ≈95% in COPD patients (2) and 80% 
in ICU patients (3). However, infection with inﬂ  uenza and 
other respiratory viruses may pose a similar risk for inva-
sive aspergillosis. Despite these high mortality rates, this 
association remains largely unnoticed (7–10). Thus, Asper-
gillus spp. observed in bronchoscopically obtained cultures 
from ICU patients diagnosed with pandemic (H1N1) 2009 
may be overlooked as a contaminant despite their potential 
to cause invasive disease.
Infection with inﬂ  uenza virus is known to cause cell-
mediated defects, disruption of normal ciliary clearance 
after infection (5), and leukopenia (6). These symptoms 
may predispose patients for invasive fungal disease. Ad-
ditionally, ARDS (11) and immunodysregulation (12) may 
develop in patients with pandemic (H1N1) 2009. Severe 
structural lung disease apparent in this syndrome may also 
impair ciliary clearance, further predisposing these patients 
to invasive infections. Data suggest a potential beneﬁ  t of 
corticosteroids in treating ARDS patients (13), but po-
tentially life-saving, high-dose corticosteroids, combined 
with structural and immunologic abnormalities observed 
in patients with pandemic (H1N1) 2009, may predispose 
patients to invasive aspergillosis. Development of this dis-
ease after inﬂ  uenza may be a rare complication. However, 
infection with pandemic (H1N1) 2009 is widespread, thus 
placing many patients at risk for invasive aspergillosis.
Previous studies of inﬂ  uenza-associated aspergillosis 
have reported mortality rates of 100% (7–10). However, 
most of these reports predate routine use of noninvasive 
markers of invasive appergillosis or availability of voricon-
azole. Previous reports were published before the availabil-
ity of oseltamivir, and speciﬁ  c antivirus therapy has been 
shown to decrease the incidence of inﬂ  uenza-associated 
complications (14,15). Early treatment with oseltamivir 
may have prevented complications seen in our patients.
Although intubated ICU patients commonly undergo 
bronchosopy, lack of a positive culture or direct smear re-
sult does not rule out a diagnosis of invasive aspergillosis 
(3). Moreover, although radiographic imaging may suggest 
aspergillosis, invasive diagnostic tests may be impractical 
when patients are hemodynamically unstable or have se-
vere hypotoxicity, thrombocytopenia, or advanced coagu-
lation deﬁ  cits (1). Before serum testing for galactomannan, 
these patients would have satisﬁ  ed criteria only for possible 
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invasive aspergillosis and appropriate treatment could have 
been withheld. However, assays for detection of serum ga-
lactomannan or 1–3-β-D glucan and compatible imaging 
studies can aid in the diagnosis of probable invasive asper-
gillosis and thus the initiation of appropriate antifungal 
therapy. With increased awareness of invasive aspergillosis 
in nontraditional hosts, high mortality rates in patients with 
this disease can be avoided.
In conclusion, we report 2 patients with invasive 
aspergillosis after infection with pandemic (H1N1) 2009. 
Development of ARDS, structural lung disease, high doses 
of corticosteroids, and T-cell defects during infection with 
inﬂ  uenza viruses may be responsible for an emerging group 
of patients at high risk for invasive aspergillosis. Early di-
agnostic and treatment strategies should be used for these 
patients, and multicenter studies are needed to better deﬁ  ne 
incidence and outcomes.
Dr Lat is a clinical manager of infectious diseases in the 
Department of Pharmacy at New York–Presbyterian Hospital, 
Columbia University Medical Center. Her research interests are 
antifungal therapy and fungal diagnostics.
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Activity Evaluation
1. Mr. Washington is a 35-year-old patient with a 2-day 
history of high fever, malaise, and cough. His son 
was diagnosed with infection with H1N1 inﬂ  uenza 
last week. None of the family was vaccinated against 
H1N1 inﬂ  uenza. He receives supportive care only for 
his symptoms. However, he presents to the emergency 
department the following week. He has experienced 
signiﬁ   cant shortness of breath, and a chest x-ray 
reveals bilateral inﬁ  ltrates. Mr. Washington is started on 
antibiotics but decompensates and develops ARDS.
Which of the following diagnostic strategies in this 
case is most appropriate if invasive aspergillosis (IA) 
is suspected?
A.   The potential inﬂ  uenza infection does not inﬂ  uence 
the risk for IA in this immunocompetent patient, and 
further assessment for IA is not indicated
B.   Bronchoscopy and culture for aspergillosis
C.   Bronchoscopy with direct smear for aspergillosis
D.   Serum galactomannan assay 
2. Mr. Washington is diagnosed with IA. On the basis of 
this activity, which of the following strategies should be 
considered?
A.   Aggressive early treatment with antiviral medications
B.   Rapid diagnosis of fungal infection after the initial 
bronchoscopy 
C.   Treatment with corticosteroids
D.  Initial treatment with voriconazole
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